A carregar...
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in p...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2721410/ https://ncbi.nlm.nih.gov/pubmed/19707382 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|